Eton Pharmaceuticals is a pharmaceutical company. Co.'s product portfolio is comprised of three categories: Orphan Drugs, which include Alkindi Sprinkle® (hydrocortisone granules), a granule hydrocortisone formulation for the treatment of Adrenocortical Insufficiency designed for use in children; Hospital Products, which include Biorphen® (phenylephrine HCl) that is indicated for the treatment of hypotension resulting primarily from vasodilation in the setting of anesthesia; and Royalty Products, which include Alaway® Preservative Free (ketotifen fumarate), a preservative-free ophthalmic product approved for the treatment of allergic conjunctivitis. The ETON average annual return since 2018 is shown above.
The Average Annual Return on the ETON average annual return since 2018 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ETON average annual return since 2018 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ETON average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|